与辉瑞就SSGJ-707 达成协议,看好其全球研发及商业化进展2025 年5 月20 日,公司及附属子公司与辉瑞签署协议,独家授予公司自主研发的突破性PD-1/VEGF 双特异性抗体SSGJ-707 在全球(不包括中国内地)的开发、生产、商业化权利。根据协议,公司将获得12.5 亿美元不可退还且不可抵扣的首付款,以及最高可达48 亿美元的开发、监管批准和销售里程碑付款。公司还将根据授权地区的产品...
Source Link与辉瑞就SSGJ-707 达成协议,看好其全球研发及商业化进展2025 年5 月20 日,公司及附属子公司与辉瑞签署协议,独家授予公司自主研发的突破性PD-1/VEGF 双特异性抗体SSGJ-707 在全球(不包括中国内地)的开发、生产、商业化权利。根据协议,公司将获得12.5 亿美元不可退还且不可抵扣的首付款,以及最高可达48 亿美元的开发、监管批准和销售里程碑付款。公司还将根据授权地区的产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.